Your Good Partner in Biology Research

  1. 首頁
  2. 蛋白
  3. 重組蛋白
  4. Recombinant Human Inosine triphosphate pyrophosphatase (ITPA)

Recombinant Human Inosine triphosphate pyrophosphatase (ITPA)

  • 中文名稱：
    人ITPA重組蛋白
  • 貨號：
    CSB-YP874838HU
  • 規(guī)格：
  • 來源：
    Yeast
  • 其他：
  • 中文名稱：
    人ITPA重組蛋白
  • 貨號：
    CSB-EP874838HU-B
  • 規(guī)格：
  • 來源：
    E.coli
  • 共軛：
    Avi-tag Biotinylated

    E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.

  • 其他：
  • 中文名稱：
    人ITPA重組蛋白
  • 貨號：
    CSB-BP874838HU
  • 規(guī)格：
  • 來源：
    Baculovirus
  • 其他：
  • 中文名稱：
    人ITPA重組蛋白
  • 貨號：
    CSB-MP874838HU
  • 規(guī)格：
  • 來源：
    Mammalian cell
  • 其他：

產(chǎn)品詳情

  • 純度：
    >85% (SDS-PAGE)
  • 基因名：
    ITPA
  • Uniprot No.：
  • 別名：
    C20orf37; dJ794I6.3; HLC14-06-P; Inosine triphosphatase (nucleoside triphosphate pyrophosphatase); Inosine triphosphatase; inosine triphosphatase-A; Inosine triphosphate pyrophosphatase; Inosine triphosphate pyrophosphohydrolase; Itpa; ITPA_HUMAN; ITPase; My049; My049 protein; Non canonical purine NTP pyrophosphatase; Non standard purine NTP pyrophosphatase; NTPase; nucleoside triphosphate diphosphatase; Nucleoside triphosphate pyrophosphatase; OK/SW-cl.9; OTTHUMP00000030094; OTTHUMP00000160459; Putative oncogene protein hlc14-06-p
  • 種屬：
    Homo sapiens (Human)
  • 蛋白長度：
    Full Length of Mature Protein
  • 表達(dá)區(qū)域：
    2-194
  • 氨基酸序列
    AASLVGKKI VFVTGNAKKL EEVVQILGDK FPCTLVAQKI DLPEYQGEPD EISIQKCQEA VRQVQGPVLV EDTCLCFNAL GGLPGPYIKW FLEKLKPEGL HQLLAGFEDK SAYALCTFAL STGDPSQPVR LFRGRTSGRI VAPRGCQDFG WDPCFQPDGY EQTYAEMPKA EKNAVSHRFR ALLELQEYFG SLAA
  • 蛋白標(biāo)簽：
    Tag?type?will?be?determined?during?the?manufacturing?process.
    The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
  • 產(chǎn)品提供形式：
    Lyophilized powder
    Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
  • 復(fù)溶：
    We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
  • 儲存條件：
    Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
  • 保質(zhì)期：
    The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
    Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
  • 貨期：
    Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
    Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
  • 注意事項(xiàng)：
    Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
  • Datasheet ：
    Please contact us to get it.

產(chǎn)品評價

靶點(diǎn)詳情

  • 功能：
    Pyrophosphatase that hydrolyzes the non-canonical purine nucleotides inosine triphosphate (ITP), deoxyinosine triphosphate (dITP) as well as 2'-deoxy-N-6-hydroxylaminopurine triposphate (dHAPTP) and xanthosine 5'-triphosphate (XTP) to their respective monophosphate derivatives. The enzyme does not distinguish between the deoxy- and ribose forms. Probably excludes non-canonical purines from RNA and DNA precursor pools, thus preventing their incorporation into RNA and DNA and avoiding chromosomal lesions.
  • 基因功能參考文獻(xiàn)：
    1. Inosine triphosphate pyrophosphatase dephosphorylates ribavirin triphosphate, and reduced enzymatic activity potentiates mutagenesis in hepatitis C virus. PMID: 30045981
    2. This study suggests that the polymorphisms in the ITPA gene influence the severity of anaemia during the first month of a DAA/RBV-based treatment in HCV-related cirrhosis. PMID: 28165327
    3. baseline testing of this single ITPA SNP might help to identify the subset of patients with the greatest risk for experiencing RBV-induced anaemia, which may be particularly helpful in those with underlying cardiovascular disease. In such patients, RBV-sparing regimens should be preferred. PMID: 28198349
    4. The authors analysed ITPA-deficient human and mouse cells, and revealed that ITPA deficiency induces MLH1/PMS2- and p53-dependent growth arrest and DNA instability in mammalian cells. PMID: 27618981
    5. ITPA variant rs1127354C>A significantly predict RBV-induced anaemia during the first 3 months of treatment and it is recommended to be assessed before RBV administration PMID: 28543275
    6. The ITPA gene polymorphism rs1127354 heterozygous genotype (CA) may influence Hemoglobin levels and protect against hemolytic anemia during ribavirin containing regimens for hepatitis C PMID: 28480960
    7. Four gene signature (PTEN, PIK3C2A, ITPA and BCL3) is an independent prognostic factors of both overall survival and disease-free survival in clear-cell renal-cell carcinoma. PMID: 27779101
    8. Inosine triphosphatase polymorphism appeared to correlate with anemia in- cidence and RBV dose reduction during SOF/RBV therapy. PMID: 28109022
    9. Inosine triphosphatase (IPTA) rs1127354 variants but not rs7270101 were found in Chinese patients infected with chronic hepatitis C. IPTA rs1127354 variants and related ITPase were not only related with ribavirin-induced hemolytic anemia but also directly affected the virological response to pegylated interferon plus ribavirin combination therapy in Chinese chronic hepatitis C virus-infected patients. PMID: 28723780
    10. This study concluded that HIV-infection seems to be interfering with the nucleotide metabolism in leukocytes, including CD4 lymphocytes, by decreasing ITPase expression, independently of ITPA genotype. PMID: 27792682
    11. A high prevalence of the ITPA polymorphisms associated with ribavirin-induced hemolytic anemia was found in Mexican Native Amerindians. PMID: 28233743
    12. ITPA gene is associated with protection of anemia in patients with chronic hepatitis during antiviral therapy. PMID: 26110293
    13. We concluded that ITPase activity plays an important function and that ATP concentration changes due to therapy are related to the Hb decreasing mechanism in the early period of therapy with HCV treatment PMID: 27040635
    14. The aim of the study was to investigate frequencies of TPMT and ITPA polymorphisms in Lithuanian inflammatory bowel disease patients and analyze their association with azathioprine-related adverse events. PMID: 26674571
    15. ITPA polymorphism was associated with RBV-induced anemia and thrombocytopenia in Egyptian patients with hepatitis C virus genotype 4 infection. PMID: 26880169
    16. Hyperbilirubinemia develops at early time points after simeprevir administration in most cases and is dependent on the ITPA genotype. PMID: 26223482
    17. Genetic variants in inosine triphosphatase (ITPA) gene have been linked to the haemolytic anaemia induced by peg-interferon and ribavirin treatment. PMID: 26104535
    18. polymorphisms increase the likelihood of developing hemolytic anemia for HCV-infected patients on RBV-based therapy, particularly rs1127354 CC and rs7270101 AA genotypes [meta-analysis] PMID: 26438033
    19. The association of IL28B and APOH single nucleotide polymorphisms (SNPs) with sustained virological response and of ITPA SNPs with anemia related phenotypes. PMID: 26670100
    20. The identification of ITPA protective and SLC29A1 risk genotypes still appears to be a current methodology in Ribavirin dosing during hepatitis C virus therapy with direct acting antiviral agents PMID: 26279293
    21. ITPA SNPs in Brazilian patients receiving antiviral therapy for chronic hepatitis had a great propensity for developing ribavirin-induced anaemia. PMID: 26154744
    22. genotyping of ATIC rs2372536 and ITPA rs1127354 variants or measuring ITPA activity could be useful to predict methotrexate response in children with juvenile idiopathic arthritis. PMID: 25240429
    23. Recessive ITPA mutations were associated with early infantile encephalopathy. PMID: 26224535
    24. results showed that patients with aberrant ITPase genotype (mutant homozygous or heterozygous), more likely to be myelosuppressed and show liver toxicity after treatment with 6-Mercaptopurine PMID: 26242828
    25. The ITPA SNP rs1127354 is a useful predictor of ribavirin-induced anemia in Taiwanese patients and may be related to more severe decreases in platelet counts during the early stage of HCV combination therapy. PMID: 25287171
    26. Results indicate a strong, significant, and independent role of VDR in the early development of ribavirin-induced anemia and confirm the ITPA function in the prediction of anemia at week 4. PMID: 25713999
    27. ITPA polymorphisms are associated with an improved likelihood of achieving sustained virological response resulting from the reduced risk of relapse following IFN and ribavirin combination therapy for HCV infection PMID: 25340831
    28. ITPA genotype may serve as a genetic marker for the improvement of risk stratification and therapy individualization for patients with acute lymphoblastic leukemia. PMID: 25303517
    29. The significant association was found between the rs1127354 ITPA gene polymorphism and protection against ribavirin-induced hemolytic anemia in the Ukrainian patients with chronic hepatitis C infection. PMID: 26030972
    30. Results show that in patients with F3-F4 chronic hepatitis C receiving telaprevir based therapy, ITPA genotype does not impact on the management of early anemia. PMID: 24760000
    31. Partial splenic embolism, in conjunction with triple combination therapy, is a useful and safe method to treat genotype 1b chronic hepatitis C patients with hypersplenism-induced thrombocytopenia PMID: 25743001
    32. the risk of mercaptopurine intolerance was decreased in acute lymphoblastic leukemia patients with 138 allele and 561 allele polymorphism in the ITPA gene PMID: 25120852
    33. important role in hepatitis C virus infection[review] PMID: 24659876
    34. For ITPA, the frequency of P32T allele was 3%. We did not observe any homozygous variant for TPMT and ITPA alleles. PMID: 24774509
    35. Irrespective of the protective effect of ITPA mutations, premenopausal females less likely develop ribavirin induced anemia. PMID: 23850877
    36. All ITPA polymorphisms considered were shown to be significantly associated with anemia onset in chronic hepatitis C treated patients. PMID: 23933495
    37. ITPA protects against ribavirin-induced anemia, but is not associated with sustained virological response rate. PMID: 24449403
    38. ITPA variants are associated with reduced risk of hepatitis C relapse. PMID: 24519039
    39. Study supports recent studies which point towards an important role for ITPase in cellular surveillance of rogue nucleotides.in hematologic malignancy. PMID: 23547827
    40. Non-CC at rs1127354 without involvement of rs7270101 is strongly associated with protection from ribavirin-induced anemia, however, inosine triphosphatase genotype is not associated with sustained virologic response. PMID: 23960450
    41. role of conserved residues in substrate specificity PMID: 23770441
    42. association between ribavirin (RBV) serum levels and SLC28A2 rs11854484 genotype, as well as the replicated association of ITPA and SLC28A3 genetic polymorphisms with RBV-induced anemia and treatment response PMID: 23195617
    43. We propose that the dimer of P32T variant subunit with wild-type subunit is degraded in cells similarly to the P32T homodimer explaining the level of loss of ITPA activity in heterozygotes. PMID: 23528839
    44. ITPA polymorphisms influenced the degree of anaemia but not thrombocytopenia during therapy of chronic hepatitis C genotype 6 infection. PMID: 23730840
    45. Rs1127354 ITPA polymorphism plays a decisive role in protecting against treatment-induced anemia and the need for ribavirin dose reduction in Egyptian hepatitis C patients. PMID: 23538996
    46. ITPA SNPs influence ribavirin-induced anemia in chronic hepatitis C. PMID: 23139603
    47. IL-28B polymorphisms and ITPA variants influence outcome of treatment for chronic hepatitis C with Peg-Interferon and ribavirin. PMID: 23301546
    48. an association was found between ITPA SNP genotype and treatment-induced anemia during a 4-week course of ribavirin monotherapy in patients with chronic hepatitis C PMID: 22460221
    49. patients with the ITPA-CC genotype showed a smaller decrease in platelet counts during natural interferon-beta/ribavirin combination therapy. PMID: 22554247
    50. ITPase C94A has been recognized in about 15% of Japanese bur recent studies on its relationship with thiopurine toxicity has not been clarified. PMID: 23126166

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Inosine triphosphate pyrophosphohydrolase deficiency (ITPAD); Epileptic encephalopathy, early infantile, 35 (EIEE35)
  • 亞細(xì)胞定位：
    Cytoplasm.
  • 蛋白家族：
    HAM1 NTPase family
  • 組織特異性：
    Ubiquitous. Highly expressed in heart, liver, sex glands, thyroid and adrenal gland.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 6176

    OMIM: 147520

    KEGG: hsa:3704

    STRING: 9606.ENSP00000369456

    UniGene: Hs.415299